IL17A and psoriasis: A variety of biologic agents have been approved for the treatment of psoriasis in China, including TNF-α inhibitors, IL-23 inhibitors, IL-17A inhibitors, IL12/23 inhibitors, etc. The widespread use of biologics in clinical settings has led to notable enhancements in the quality of life for individuals affected by psoriasis (8).